il 34 levels (R&D Systems)
Structured Review
Il 34 Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/il+34+levels/Human+IL-34+Quantikine+ELISA+Kit/pm40381116-47-10-17
Average 93 stars, based on 19 article reviews
Images
Related Articles
Clinical Proteomics:Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study. Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and Enzyme-linked Immunosorbent Assay:Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study. Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and Flow Cytometry:Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study. Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and |

